Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

BACKGROUND: The hedgehog (HH) signaling pathway is a key regulator in tumorigenesis of pancreatic adenocarcinoma (PDA) and is up-regulated in PDA cancer stem cells (CSCs). GDC-0449 is an oral small-molecule inhibitor of HH pathway. This study assessed the effect of GDC-0449-mediated HH inhibition in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Kim, Edward J., Sahai, Vaibhav, Abel, Ethan V., Griffith, Kent A., Greenson, Joel K., Takebe, Naoko, Khan, Gazala N., Blau, John L., Craig, Ronald, Balis, Ulysses G., Zalupski, Mark M., Simeone, Diane M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4254161/
https://ncbi.nlm.nih.gov/pubmed/25278454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1269
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk